Browsing Tag
Janus Henderson Investors
4 posts
Equillium secures financing to launch EQ504 Phase 1 trial in 2026
Equillium secures up to $50M to fund clinical entry of EQ504 mid-2026—discover how this financing shapes its immunology strategy.
Parse Biosciences secures $50m in Series C for single cell sequencing
Parse Biosciences has announced a significant milestone in their funding journey, securing a total of $50 million through…
Pyxis Oncology raises $152m in Series B round for cancer therapies
Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by…
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million…